
Loading, please wait...

Loading, please wait...

Recent breakthroughs in neurophysiology suggest that Alzheimer's disease (AD) involves more than just cognitive decline. It significantly impacts the EEG-HRV coupling in Alzheimer's, disrupting the critical communication between the brain and the heart. This narrative review highlights how integrating electroencephalography (EEG) and heart-rate variability (HRV) can transform early diagnosis and personalized management for patients.
Physiological balance relies on the central autonomic network (CAN), which links cortical activity to the heart's rhythm. In healthy individuals, the brain and heart communicate effectively to respond to internal and external demands. However, patients with neurovisceral decline show a shared loss of coordination between these systems. Studies consistently indicate that integrated EEG-HRV metrics provide higher accuracy than either measure alone. Specifically, this combined biomarker helps distinguish mild cognitive impairment (MCI) from early AD with greater precision. Furthermore, these changes often appear before structural brain atrophy becomes visible on conventional imaging.
Current diagnostic hurdles include inconsistent recording protocols and a lack of standardized analytic methods. To address these, researchers propose a translational roadmap for clinical validation. Moreover, this plan involves the integration of wearables and digital health applications. Consequently, clinicians could monitor patients in real-world settings rather than just in specialized laboratories. Ultimately, this approach makes Alzheimer's screening more scalable and accessible across diverse populations like those in India.
Combining EEG and HRV provides a holistic view of the central autonomic network. While EEG measures brain electrical activity and HRV reflects cardiac flexibility, their coupling reveals how well the two systems communicate. This integration offers a more sensitive indicator of neurovisceral decline than individual assessments.
Yes, research suggests that disruptions in brain-heart communication often precede significant memory loss. By identifying these early physiological imbalances, clinicians can implement interventions sooner to potentially slow disease progression.
While the evidence is strong, the tool is currently transitioning from research to clinical validation. Standardizing recording conditions and analytic methods is essential before it becomes a routine part of Alzheimer's care in hospitals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This review highlights EEG-HRV coupling as a superior biomarker for early Alzheimer's diagnosis, reflecting the loss of brain-heart communication in patient...
7 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

Odisha has established India's first state-level clinical protocol specifically tailored for pregnant women with sickle cell disease. Developed with NHM and UNICEF, the framework provides structured antenatal screening, crisis mitigation, standardized referral pathways, and specialized interdisciplinary care.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today